GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (FRA:8IY) » Definitions » Common Stock

Yumanity Therapeutics (FRA:8IY) Common Stock : €0.01 Mil (As of Sep. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics Common Stock?

Yumanity Therapeutics's quarterly common stock stayed the same from Mar. 2022 (€0.01 Mil) to Jun. 2022 (€0.01 Mil) but then increased from Jun. 2022 (€0.01 Mil) to Sep. 2022 (€0.01 Mil).

Yumanity Therapeutics's annual common stock declined from Dec. 2019 (€4.61 Mil) to Dec. 2020 (€0.01 Mil) but then increased from Dec. 2020 (€0.01 Mil) to Dec. 2021 (€0.01 Mil).


Yumanity Therapeutics Common Stock Historical Data

The historical data trend for Yumanity Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics Common Stock Chart

Yumanity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21
Common Stock
4.61 0.01 0.01

Yumanity Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Yumanity Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Yumanity Therapeutics (FRA:8IY) Business Description

Traded in Other Exchanges
N/A
Address
40 Guest Street, Suite 4410, Boston, MA, USA, 02135
Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Yumanity Therapeutics (FRA:8IY) Headlines

No Headlines